Congress deregulates medicine—except abortion, gender care, assisted suicide

What it does

This bill strips the FDA, NIH, and CDC of authority to regulate medical practice and prohibits federal law from restricting off-label drug use. However, it explicitly carves out abortion, assisted suicide, euthanasia, and gender-transition medical interventions from this protection—meaning federal restrictions on those practices remain enforceable. The bill's net effect is to deregulate most medical practice while preserving or enabling federal bans on specific categories of care.

Why we flagged it

The bill's operative mechanism is broad deregulation of medical practice and off-label drug use, but the carve-out in subsection (b) reveals the true character: it is not neutral deregulation but a selective framework that removes federal oversight from most medicine while affirmatively preserving federal authority to restrict abortion, gender-transition care, and assisted suicide. This is deregulation-with-exceptions, not pure deregulation.

What the text implies

• The carve-out in subsection (b) does not merely preserve existing law—it affirmatively signals that federal restrictions on abortion, gender-transition care, and assisted suicide are INTENDED to remain enforceable and may be strengthened. This invites future federal bans on those practices.
• Removing FDA authority to regulate medical practice may eliminate safety oversight for experimental treatments, compounded-drug quality, and off-label prescribing protocols, shifting liability and safety burden to individual physicians and patients.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical companies (off-label drug sales without FDA gatekeeping); compounding pharmacies (reduced federal oversight of compounded drugs); physicians and medical practices (reduced regulatory compliance burden)